Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Review

    Relugolix: A Novel Gonadotropin‑Releasing Hormone Antagonist for Prostate Cancer

    Merin Babu1, Keechilat Pavithran2★★ Corresponding author

    1. 1Department of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
    2. 2Department of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.

    CORRESPONDENCE

    Keechilat Pavithran

    Department of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Ponekkara, Kochi ‑ 682 041, Kerala, India.

    pavithrank@aims.amrita.edu

    Received: 23-12-2020; Revised: 22-01-2021; Accepted: 26-01-2021.

    Volume 12, Issue 1 · pp. 26–28 · PUBLISHED 5 July 2021 · DOI: 10.4103/jpp.jpp_170_20

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Androgen deprivation therapy (ADT) is currently the mainstay of treatment for advanced prostate cancer. The peptide formulations of gonadotropin‑releasing hormone (GnRH) antagonists need to be given subcutaneously every month. This led to the development of an oral, nonpeptide GnRH antagonist formulation relugolix which promptly lowers the levels of testosterone, luteinizing hormone, and follicular‑stimulating hormone. On December 18, 2020, the US Food and Drug Administration approved relugolix for the treatment of adult advanced prostate cancer. The recommended loading dose of 360 mg on the 1st day of treatment, followed by 120 mg once daily orally, approximately the same time each day. The maximum plasma concentration (Tmax) is obtained within 2.25 h and is metabolized to a major extent by CYP3A mediated mechanism. Hot flushes, musculoskeletal pain, and fatigue are some of its common adverse effects. High rates of testosterone suppression with a limited adverse event profile make it an ideal therapy for the treatment of advanced prostate cancer.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Babu, M., & Pavithran, K. (2021). Relugolix: A Novel Gonadotropin‑Releasing Hormone Antagonist for Prostate Cancer. Journal of Pharmacology and Pharmacotherapeutics, 12(1), 26–28. https://doi.org/10.4103/jpp.jpp_170_20